Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A1 | P46059 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12369646 | 1.00 | SLC15A1 (0.59) | SLC15A1ALDH1A1MAPK1L3MBTL1MMP9 | |
| SCHEMBL4900863 | 1.00 | SLC15A1 (0.59) | SLC15A1ALDH1A1MAPK1L3MBTL1MMP9 | |
| SCHEMBL9636201 | 0.90 | ALDH1A1 (0.58) | SLC15A1ALDH1A1MAPK1L3MBTL1MMP9 | |
| SCHEMBL14194794 | 0.88 | SLC15A1 (0.58) | SLC15A1ALDH1A1MAPK1L3MBTL1MMP9 | |
| SCHEMBL4908110 | 0.88 | ALDH1A1 (0.58) | SLC15A1ALDH1A1MAPK1L3MBTL1MMP9 | |
| SCHEMBL16379300 | 0.87 | ALDH1A1 (0.54) | SLC15A1ALDH1A1MAPK1L3MBTL1MMP9 | |
| SCHEMBL12282025 | 0.87 | ALDH1A1 (0.54) | SLC15A1ALDH1A1MAPK1L3MBTL1MMP9 | |
| SCHEMBL18300829 | 0.87 | ALDH1A1 (0.56) | SLC15A1ALDH1A1MAPK1L3MBTL1MMP9 | |
| SCHEMBL111390 | 0.86 | ALDH1A1 (0.61) | SLC15A1ALDH1A1MAPK1L3MBTL1MMP9 | |
| SCHEMBL31558356 | 0.85 | ALDH1A1 (0.53) | SLC15A1ALDH1A1MAPK1L3MBTL1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119019400-A | Prodrugs of GS-441524 and medical application thereof | 中国药科大学 | 2024-11-26 | — | — | CN | disclosed |
| WO-2023240156-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES, AND METHODS OF SYNTHESIS AND USE THEREOF | TIDAL THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-2673281-B1 | BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTICS USES THEREOF | REMPEX PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | disclosed |
| US-8791162-B2 | Cathepsin cysteine protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8540966-B2 | Contrast agents endowed with high relaxivity | BRACCO IMAGING S.P.A. (IT) | 2013-09-24 | — | — | US | disclosed |
| US-20120329724-A1 | PEPTIDE ANALOGUES | PFIZER LIMITED | 2012-12-27 | — | — | US | disclosed |
| US-20120010161-A1 | NOVEL AZAPEPTIDE OR AZAPEPTIDOMIMETIC COMPOUNDS INHIBITING BCRP AND/OR P-GP | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-01-12 | — | — | US | disclosed |
| US-20110256067-A1 | Contrast agents endowed with high relaxivity | BRACCO IMAGING SPA (IT) | 2011-10-20 | — | — | US | disclosed |
| US-20110207654-A1 | PEPTIDE ANALOGUES | PFIZER INC. | 2011-08-25 | — | — | US | disclosed |
| US-7988950-B2 | Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (MRI) which contain a chelating moiety with polyhydroxylated substituents | BRACCO IMAGING S.P.A. (IT) | 2011-08-02 | — | — | US | disclosed |
| EP-1148050-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-0641325-B1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO CO (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6180646-B1 | PREVENT REPRODUCTION OF RETROVIRUS | MONSANTO COMPANY | 2001-01-30 | — | — | US | disclosed |
| EP-0957093-A2 | Retrovial protease inhibitors | MONSANTO COMPANY (US) | 1999-11-17 | — | — | EP | disclosed |
| US-5948790-A | VIRICIDES | MOSANTO COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| US-5756534-A | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 1998-05-26 | — | — | US | disclosed |
| US-5648364-A | HETEROCYCLIC PEPTIDE COMPOUNDS AS ENZYME INHIBITORS | MONSANTO COMPANY (US) | 1997-07-15 | — | — | US | disclosed |
| US-5643924-A | Retroviral protease inhibitors | MONSANTO COMPANY OF ST. LOUIS (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0641325-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1993023379-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110256067-A1 | Contrast agents endowed with high relaxivity | SLC40A1, SLC67A1, SLC19A1 | SLC15A1 88/4885ALDH1A1 2186/4885MAPK1 2492/4885 |
| US-20120010161-A1 | NOVEL AZAPEPTIDE OR AZAPEPTIDOMIMETIC COMPOUNDS INHIBITING BCRP AND/OR P-GP | ABCB1, ABCB11, ABCC1 | SLC15A1 576/4885ALDH1A1 2049/4885MAPK1 2470/4885 |
| US-20120329724-A1 | PEPTIDE ANALOGUES | OPRL1, OGFR, OPRM1 | SLC15A1 870/4885ALDH1A1 2652/4885MAPK1 1895/4885 |
| US-20110207654-A1 | PEPTIDE ANALOGUES | OPRL1, OGFR, OPRM1 | SLC15A1 870/4885ALDH1A1 2652/4885MAPK1 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.